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Key Points 
 Ruxolitinib showed no significant improvement for attainment of either CR or PR over BAT 
within the first year of therapy in high-risk ET 
 Ruxolitinib significantly improved some disease-related symptoms but rates of thrombosis, 
hemorrhage or transformation were not different 
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Abstract  
Treatments for high-risk essential thrombocythemia (ET) address thrombocytosis, disease-related 
symptoms, as well as risks of thrombosis, hemorrhage, transformation to myelofibrosis and 
leukemia. Patients resistant/intolerant to hydroxycarbamide (HC) have a poor outlook.  MAJIC 
(ISRCTN61925716) is a randomized phase II trial of ruxolitinib (JAK1/2 inhibitor) vs Best Available 
Therapy (BAT) in ET and polycythemia vera (PV) patients resistant or intolerant to HC. Here findings 
of MAJIC-ET are reported, where the modified intention-to-treat population included 58 & 52 
patients randomized to receive ruxolitinib or BAT respectively. There was no evidence of 
improvement in complete response within 1 year reported in 27 (46.6%) patients treated with 
ruxolitinib vs 23 (44.2%) with BAT (P=.40). At 2 years rates of thrombosis, hemorrhage and 
transformation were not significantly different, however some disease-related symptoms improved 
in patients receiving ruxolitinib relative to BAT. Molecular responses were uncommon; there were 
two complete molecular responses (CMR) and one partial molecular response (PMR) in CALR 
positive ruxolitinib-treated patients. Transformation to myelofibrosis occurred in one CMR patient, 
presumably due to the emergence of a different clone raising questions about the relevance of CMR 
in ET patients. Grade 3&4 anemia occurred in 19% & 0% of ruxolitinib vs 0% (both grades) BAT arm, 
grade 3&4 thrombocytopenia in 5.2% & 1.7% of ruxolitinib vs 0% (both grades) of BAT treated 
patients. Rates of discontinuation or treatment switching did not differ between the two trial arms. 
The MAJIC-ET trial suggests that ruxolitinib is not superior to current second-line treatments for ET. 
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Introduction 
Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN) characterized by 
thrombocytosis. Patients are at higher risk of thrombosis and hemorrhage. They also have disease-
related symptoms, which are difficult to manage with standard therapies. Therapeutic approaches 
address risks of thrombosis and hemorrhage, without increasing transformation into myelofibrosis 
(PET-MF) or acute myeloid leukemia (AML) 1-3. Low-dose aspirin with hydroxycarbamide (HC) is 
recommended first-line therapy in high-risk patients, supported by data from randomized trials3,4. 
Approximately 20% of ET patients become HC-intolerant or resistant; patients with resistance 
appear to be at increased risk of disease transformation and reduced overall survival5. No 
prospective trial data exists to guide management of ET patients who are HC-resistant or intolerant; 
treatment options are limited, and several second-line treatment options are associated with 
increased risk of disease transformation2,3,6. 
The discovery of the Janus kinase (JAK2V617F) mutation provided the first genetic marker of the 
malignant clone in MPN7-9.  Furthermore, other key driver mutations associated with ET, affecting 
thrombopoietin receptor MPL and calreticulin (CALR) also lead to increased JAK2 signaling14. The 
JAK1/2 inhibitor, ruxolitinib, was effective in reducing spleen volume, controlling blood counts and 
improving symptoms in MF and PV patients15-17.  Ruxolitinib treatment may also result in a survival 
advantage for patients with MF18,19. A previous non-randomized study in 39 ET patients, resistant or 
intolerant to HC, demonstrated that ruxolitinib lowered both platelet and white cell counts and the 
most effective starting dose was 25mg bd20. 
 
We conducted a randomized, phase II trial to evaluate the activity and safety of ruxolitinib vs Best 
Available Therapy (BAT) in two different patient populations (ET and PV): A randomized study of best 
Available therapy versus JAK inhibition in patients with high-risk PV or ET who are resistant or 
intolerant to HydroxyCabamide (MAJIC). The study utilized an efficient framework of a basket trial 
design, permitting the separate evaluation of two study populations. Here we present safety and 
efficacy data for the ET population, so-called MAJIC-ET.  
Patients and Methods 
Trial design 
An independent, parallel, open-label, randomized controlled trial of ruxolitinib vs BAT was 
implemented (Supplemental Figure S1). Patients aged ≥18 with high-risk ET or PV, who met modified 
criteria for intolerance or resistance to HC21 (Supplemental Table S1), were recruited. MAJIC-PV arm 
is on-going. High-risk ET was defined by standard criteria (Supplemental Table S2). Patients were 
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stratified by JAK2V617F status and randomized 1:1 to receive either ruxolitinib (starting dose 25mg 
twice daily (bd) or 20mg bd, if baseline platelets were 100-200×109/L) or BAT. Inclusion and 
exclusion criteria are presented (Supplemental Table S3). The trial was registered at www.isrctn.com 
(ISRCTN61925716) and reviewed by an independent research ethics committee. All participants gave 
written informed consent in accordance with the Declaration of Helsinki. Trial data was analyzed by 
statisticians at the Cancer Research UK Clinical Trials Unit (University of Birmingham) and Quality of 
Life (QoL) analysis performed by statisticians at the Mayo Clinic, Scottsdale, Phoenix. Ruxolitinib was 
provided free of charge by Novartis. All authors had access to primary clinical trials data and 
approved the final version of manuscript.   
Outcome measures 
The primary outcome measure was achievement of Complete Response (CR) as defined by European 
Leukemia Net (ELN) criteria within 1 year of treatment22. CR in ET patients was defined by achieving 
all of the following criteria: platelet count ≤400×109/L; normal spleen size on imaging; white blood 
cell count ≤10×109/L. Secondary outcomes included Partial Response (PR)  per ELN criteria within 1 
year of treatment, duration of response (both CR and PR) and overall response (i.e. CR&PR), toxicity 
profile of ruxolitinib based on National Cancer Institute Common Terminology Criteria for Adverse 
Events (NCI CTCAE) version 4, dose intensity, histological response, molecular response; 
hemorrhagic and thromboembolic events, disease transformations, QoL and disease symptom 
burden, overall and progression free survival. The safety population included all patients who 
received at least one dose of protocol treatment. Hemorrhagic and thrombotic events were centrally 
reviewed. QoL and symptom assessment questionnaires: 10-item Myeloproliferative Neoplasm 
Symptom Assessment Form (MPN-10) Total Symptom Score (TSS)23, EQ-5D24 and M.D. Anderson 
Symptom Inventory (MDASI)25 were completed at baseline (pre-treatment, 7 consecutive days for 
the MPN-10 and once for the other questionnaires), 2 and 4 months post randomization and 
continued 4 monthly whilst on trial. Overall symptom response was defined as at least a 50% 
reduction in TSS from baseline (average of the 7 baseline days with at least 4 of 7 days scored) at any 
post-baseline time point up to Month 12. 
Sample size justification and statistical analysis 
Sample size calculations were based upon rates from a previous phase II study20 using an one-sided 
normal test without continuity correction and unpooled variance. CR rate for controls was estimated 
at 30%. A clinically significant improvement was considered to be 20%. Thus, assuming CR rates in 
the control and treatment group were 30% and 50%, 55 patients were required in each arm to 
detect a clinically significant difference of 20% with 82% statistical power at 10% level of 
significance. As this is a randomized screening trial to evaluate a direct, but nondefinitive 
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comparison, with the aim of screening for promising signal of activity in ruxolitinib, a relaxed one-
sided significance level of 10% was utilized26. Allowing for a 5% drop out rate, 116 patients were 
required.  
 
P<.10 was considered significant for the primary outcome. For other analyses, two-sided tests were 
used and a P<.05 was considered significant. Number and proportion of patients reported for 
categorical variables by treatment group and overall. Descriptive statistics (number of patients, 
mean, standard deviation (SD), median, Interquartile Range (IQR)) reported for continuous variables 
by treatment group and overall. Time-to-event outcomes analyzed using the method of Kaplan and 
Meier and differences in survival time determined using a Cox’s model with adjustment for 
JAK2V617F status per baseline data. Sensitivity analysis adjusting the Cox models for hemoglobin 
and disease duration were performed and reported where treatment effect differed. Normal Z-tests 
were used to assess difference in proportions. Univariate and multivariate logistic regression were 
fitted models to assess effect of baseline measures on primary outcome, transformations and 
toxicity. Apart from the primary outcome, additional hypotheses testing were exploratory and non 
pre-specified. All summaries and statistical analyses for efficacy were primarily carried out on a 
modified intention to treat (mITT) basis, including patients analyzed according to their randomized 
treatment allocation, starting treatment within one year of randomization and with at least one 
response. Summary statistics for safety variables were based on the safety population, which 
included patients according to the treatment they actually received and who received >1 doses of 
treatment. Statistical analyses were performed using Stata version 14.2. 
 
QoL and symptom data were analyzed in mITT population using SAS version 4. Symptom response 
rate was compared using chi-squared test, maximum percentage reduction from baseline during the 
first 12 months using a Wilcoxon rank-sum test. Symptom response and percentage reduction at 
post-baseline time points (or at most recent assessment if no symptom data at the given time point 
were provided) were compared using chi-squared and Wilcoxon rank-sum tests. Comparisons of 
mean scores longitudinally employed a linear mixed model for each outcome (from month 2 
assessment) using all available data. In addition each model included a continuous covariate for 
baseline value of outcome and used planned month of assessment as categorical time value with 
compound covariance structure. 
Treatment and assessments 
Ruxolitinib was initiated based on baseline platelet count. BAT was assigned according to physician’s 
choice but had to be an active agent, change of and combination of BAT therapies was permitted 
with the aim of achieving a CR. No crossover of BAT to ruxolitinib was permitted. Low-dose aspirin 
6                                                  BLOOD/2017/785790    v 2.0 Resubmission MAJIC ET_Main Manuscript 
 
(75mg od) was advised unless contraindicated. Protocol-specified dose reductions for ruxolitinib 
were in place and patients allowed to re-escalate if toxicity had resolved. Lowest permitted dose of 
ruxolitinib was 5mg once-daily. Hematological response was assessed 2 weekly for 3 months, then 6 
weekly in order to determine the primary outcome of CR during year 1 (cut-off week 54).  
Ultrasound was performed at baseline and centrally reviewed. If splenomegaly was present at 
baseline repeat ultrasound showing resolution was required for CR. Ruxolitinib continued beyond 1 
year if CR or PR were maintained. Those discontinuing ruxolitinib moved to BAT arm for follow-up. 
Patients who transformed to PET-MF, myelodysplastic syndrome (MDS) or AML discontinued the 
trial but were followed for survival. 
 
Assays for JAK2V617F, CALR and MPL mutation allele burden was quantified using next generation 
sequencing as previously described27. An analysis of histological features is currently being 
performed and this data is not being presented as part of this manuscript. 
Results 
Patient characteristics  
116 patients were recruited in 31 UK centers between September 2012-February 2015, median 
follow up of 2.61 years (range: 0.23 – 4.12).  In total 110 were eligible for the mITT analysis, 
comprising 58 (52%) and 52 (48%) patients in the ruxolitinib and BAT arms respectively. Median age 
of patients was 64.2 years with 44 (40%) males and 66 (60%) female patients, overall 28/110 (25.4%) 
were resistant to HC, 57/110 (51.8%) intolerant or 25/110 (22.7%) both. Baseline characteristics 
were balanced (Table 1), except for the ruxolitinib arm with longer disease-duration and lower 
hemoglobin. Six patients were excluded from mITT analysis: 4 withdrew without treatment (2 did 
not wish to be on BAT arm, one ineligible, one had transformed to PET-MF) and 2 did not start 
treatment within one year from randomization.  All CALR indels and MPL mutations are provided in 
Supplemental Table S4. 
Trial Treatment 
For patients receiving ruxolitinib, the mean dose intensity of ruxolitinib during year one was 19mg 
bd (Figure 1). The most common BAT therapies utilized at least once included HC in 37/52 (71.1%), 
anagrelide in 25/52 (48.1%) and interferon in 21/52 (40.4%) patients.  
Patient disposition  
Patient disposition at the time of analysis (2 year follow up) is shown in Figure 2. Thirty BAT patients 
(57.7%) switched their initially assigned therapy at least once and there were 86 switches across the 
BAT group.  In total, 45 patients (49.5%) discontinued treatment, with 40 discontinuations occurring 
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within the first treatment year. Thirty-five patients (60.3%) receiving ruxolitinib and 10 patients 
(19.2%) receiving BAT discontinued treatment. The main reasons for discontinuation in the 
ruxolitinib arm were loss of response (11/35 (31.4%)) and transformation (9/35 (25.7%)). The main 
reasons for discontinuation in the BAT arm were transformation (3/10 (30%]) and death (2/10 
(20%)). Discontinuations and therapy switches are shown in Table 2. 
Efficacy analysis 
For patients meeting the criteria for mITT analysis the primary outcome (CR) was achieved in 27 
(46.5%) of the patients in the ruxolitinib arm vs 23 (44.2%) in the BAT arm (Unadjusted P=.40, 
adjusted for JAK2V617F status P=.40) with a difference of proportions -2.3% between BAT and 
ruxolitinb (80% CI: -15%, 10%). PR occurred in 27 (46.5%) patients in the ruxolitinib arm and 27 
(51.9%) patients in the BAT arm. Time to first response (CR or PR) between the two arms was 
significantly different (P=.01) with BAT patients taking longer. Duration of CR appeared shorter for 
ruxolitinib patients (borderline significant difference, P=.05; adjustment for hemoglobin and disease 
duration rendered this insignificant, P=.2).  There was no evidence of a difference in duration of 
overall response between ruxolitinib and BAT. Overall survival (OS) and progression free survival 
(PFS) at 1 year were similar (OS: .98 (95%CI .86, .99) for BAT and .98 (95%CI 0.88, 0.99) for ruxolitinib 
patients, PFS: .96 (95%CI .85, .99) for BAT and .93 (95%CI .81, .97) for ruxolitinib patients). In 
multivariable analyses performed to assess baseline factors influencing CR (modelled for: treatment 
received, HC resistance/intolerance, white cell count, platelets, hemoglobin & JAK2/CALR status) no 
factor was shown to be significant and did not change the treatment effect (Supplemental Table S5). 
Thrombosis, hemorrhage and disease transformation 
After 2 years of follow up transformation to PET-MF occurred in 8 ruxolitinib vs. 5 BAT treated 
patients. Transformation to AML was seen in 1 patient who received ruxolitinib. Transformation-free 
probability was not significantly different between the two arms (P=.29; Supplemental Figure S2A). 
Concerning thrombosis and hemorrhage, following central review, 10 patients (17.2%) on the 
ruxolitinib arm experienced 11 thrombotic events compared to 3 patients (5.8%) on the BAT arm 
experiencing 5 events. Hemorrhagic events were 1 (1.7%) vs 5 (8.9%) for ruxolitinib and BAT patients 
respectively (Table 3). Concerning thrombosis-free probability, the differences were borderline but 
not statistically significant (P =.09; Supplemental Figure S2B). Hemorrhage was less frequent for 
patients treated with ruxolitinib, however this difference was also not significant (P =.14; 
Supplemental Figure S2C). Since all of these events are considered clinically relevant we performed 
an analysis of transformation, thrombosis and hemorrhage as a composite endpoint; there was no 
evidence of a difference (P =.35; Supplemental Figure S2D). Most thrombotic and hemorrhagic 
events occurred in patients in CR or PR (Supplemental Figure S3). In a multivariate analysis of factors 
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influencing transformation to PET-MF, this event only occurred in patients with baseline WBC 
<10×109/L (Supplemental Table S6). 
Molecular responses (MR) 
The mean baseline allele burdens for JAK2V617F, CALR or MPL mutation positive patients are 
displayed in Table 1. At 12 months, or the last available sample during year 1, the overall mean allele 
burden had not changed significantly for any mutation in either treatment arm. However, 1 
complete molecular response (CMR) and 1 partial molecular response (PMR) per ELN criteria were 
seen for JAK2V617F positive patients on the ruxolitinib arm and 2 CMRs and 1 PMR for CALR positive 
patients on ruxolitinib compared to 0 CMRs/PMRs for patients with these mutations receiving BAT. A 
JAK2V617F positive patient who achieved a PMR on ruxolitinib also had resolution of a cytogenetic 
abnormality at one year. There was no pattern of MR or progression with complete or partial 
hematological response or transformation, but 1 CALR positive patient who transformed to PET-MF 
had a CMR. 
Impact on ET Related Disease Symptom Burden 
Among 110 patients in the mITT cohort, 85 completed the baseline and at least one post-baseline 
questionnaire (ruxolitinib N=47, BAT N=38). While overall symptom response rate during the first 12 
months did not significantly differ between arms (ruxolitinib 12/42 (29%) vs BAT 6/31 (19%), P=.37), 
maximum percentage TSS reduction at any point during the first 12 months of treatment was 
significantly greater for ruxolitinib compared to BAT (median reduction 32% vs 0%, P=.03, Figure 3A). 
Symptom response was rapid in the ruxolitinib arm (8/42 (19%) at 2 months) as compared to BAT 
(1/31 (3%) at 2 months, P =.04). Longitudinally, mean TSS (P=.03) and the individual symptom of 
pruritus (P=.01) were significantly lower for ruxolitinib vs BAT (Figure 3B and 3C), with trends 
observed for improved concentration (P=.05), lower anxiety/depression (EQ5D P=.09), and higher 
ability to perform usual activities (EQ5D P=.09) on the ruxolitinib arm compared to BAT. 
Safety 
All safety analysis was conducted on the safety population: 115 patients (57 BAT, 58 ruxolitinib). A 
total of 128 Grade 3/4 events occurred in 89 patients on the trial (Supplemental Table S7). 
Hematological toxicities (36/128) and metabolism/nutrition disorders (17/128 – 10 relating to 
hyponatremia) were the most common.  Grade 3 or 4 anemia occurred in 12/58 (21%) of ruxolitinib 
patients vs 0/57 (0%) in the BAT patients (P<.005), grade 3 or 4 thrombocytopenia in 2/58 (3.4%) of 
ruxolitinib vs 0/57 (0%) of BAT patients (P=.32), and grade 3 (only) infections occurred in 9/58 
(15.5%) of patients in the ruxolitinib arm compared to 2/57 (3.5%) (grade 3 and 4) in the BAT arm 
(P=.03). Overall 2 patients discontinued ruxolitinib for anemia; there were no discontinuations 
related to thrombocytopenia. Blood counts during the trial according to treatment arm are shown in 
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Supplemental Figure S4, demonstrating equivalent control of leucocytes and platelets but lower 
hemoglobin from week 4. An unplanned multivariate model (modelled for hemoglobin (≥ 100g/dl) 
and JAK2/CALR status) demonstrated that baseline hemoglobin (≥100g/dl) was significant in 
predicting the occurrence of anemia or thrombocytopenia (OR=.17, 95% CI=.04, .72, P=.01) 
(Supplemental Table S8). 
There were 5 patient deaths in the ruxolitinib arm and 2 in the BAT arm, none were considered 
treatment related. The deaths in the BAT arm were due to multiple organ failure and cerebral 
hemorrhage. In the ruxolitinib arm, deaths were due to carcinomatosis combined with esophageal 
cancer, bowel infarction due to adhesions, acute left ventricular failure, ischemic cardiomyopathy 
and sepsis combined with pancreatic cancer.  
Discussion  
ET is often regarded as the most indolent of the Philadelphia negative MPNs, treatments offer 
improvements in blood counts and reduction in risk of thrombosis and hemorrhage with a lack of 
certainty regarding effects upon transformation to PET-MF and AML2,3. Criteria for resistance or 
intolerance to therapy with HC were originally developed to guide clinicians when to initiate second-
line therapies; however, there is now evidence that HC resistant patients have a poor outlook28. In 
addition, disease-related symptom burden is increasingly recognized as an important disease 
feature, causing significant morbidity with few effective treatments2-4. In previous studies patients 
with MF gained a  survival benefit with ruxolitinib, which also reduced spleen size and symptoms 
compared to BAT18. In the RESPONSE study in HC resistant/intolerant PV patients there was a 
suggestion of lower rates of thrombosis in patients receiving ruxolitinib compared with BAT, as well 
as better control of blood counts, spleen size and symptoms17. 
The MAJIC trial was designed to compare ruxolitinib with BAT in patients with HC intolerance/ 
resistance in two populations, MAJIC-ET and MAJIC-PV. Both trial populations are fully recruited and 
here we report the findings of MAJIC-ET trial. The patients recruited into MAJIC-ET displayed 
characteristics that were well-balanced between the two arms with the exception of baseline 
hemoglobin and prior disease duration. Distribution of driver mutations JAK2V617F, MPL exon 10, 
CALR mutations were as expected. Our patients had a long disease duration (up to 31 years) some of 
whom had received multiple therapy lines with up to nine prior therapies. Some features of 
advanced disease, for example splenomegaly and leukocytosis, were present at baseline however 
transformation to PET-MF was excluded at trial entry. Diagnostic criteria have been controversial in 
ET and those in use at trial centers were: British Committee for Standards in Hematology (BCSH 
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n=18); WHO 2001/2008 (n=10) and both combined (n=3). The BCSH and WHO criteria were recently 
shown to perform equally well29.  
 
Usual therapy choice in the second-line setting for ET would be anagrelide or interferon, however in 
order to perform a “real-life comparison” we allowed investigator choice. Overall the majority, 79% 
(41/52), of BAT patients received one or both agents before or during the study. On-study BAT 
included in addition busulfan 32P and HC; several international guidelines recommend busulfan or 32P 
for older patients.  
 
Proportions of patients reaching CR within one year were similar: 27 (46.5%) in the ruxolitinib arm vs 
23 (44.2%) for BAT, with similar PR rates. Time to any first response (CR or PR) was significantly 
faster for patients treated with ruxolitinib (P=.01). A particularly interesting finding, as patients in CR 
who were randomized to receive ruxolitinib had to change therapy and potentially lost any pre-
existing response yet managed to attain CR faster than BAT patients who may not have changed 
therapy thus only needing to maintain response. In addition, BAT patients were also allowed to 
combine or to switch therapies and frequently did so. Importantly the duration of CR appeared 
shorter for ruxolitinib patients with a marginally significant value, while the duration of overall 
response (CR and PR) was not different between both arms. We confirm that HC resistant/intolerant 
ET patients have a high-risk of thrombosis, hemorrhage and transformation to PET-MF; event rates 
here being higher than reported in the non-resistant/intolerant patients e.g. PT-1 or ANAHYDRET 
studies30,31. However, overall thrombosis, hemorrhage or transformation considered separately or 
together as a composite endpoint were not statistically different between the ruxolitinib and BAT. 
Furthermore, in a post hoc unplanned analysis for factor influencing transformation to PET-MF, only 
a leucocyte count <10x109/L was significant.  
Studies have reported that post-randomization exclusions of patients in randomized trials may affect 
trial results32, with some raising concerns that the investigated therapy might be favored33,34. 
However, in the MAJIC-ET trial, if we were to conduct a pure intention-to-treat (ITT) analysis, this 
would require imputation of missing response data for 6 BAT patients. Missing data imputation may 
bias estimates of treatment effects35.  A commonly used technique is nonresponder imputation, 
which will attribute all 6 BAT patients as not achieving CR within a year. This will result in a less 
conservative ITT analysis of 23/58 CR (BAT) vs 27/58 CR, with p-value of .22 compared to the mITT 
analysis (p=.4). Our primary findings of no evidence of superiority of ruxolitinib were however 
consistent using either mITT or ITT analysis. 
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Molecular responses were uncommon in the first year of the trial, as described previously20. 
However, ruxolitinib was associated with two CMR and one PMR in a CALR positive patient; this has 
not previously been reported. Transformation to PET-MF in one CALR positive patient, who achieved 
a CMR, presumably occurred due to the emergence of a different clone, consistent with patients 
reported with JAK2V617F positive chronic phase developing JAK2V617F negative AML36, and raises 
questions about the relevance and value of CMR in patients with ET.  
Patterns of adverse events with ruxolitinib were similar to those already reported, most prevalent 
events related to hematological, nutritional and metabolic events. Infections were also more 
common with ruxolitinib therapy. There was no suggestion of imbalance between the two arms of 
MAJIC-ET for non-melanoma skin cancer as was previously noted in the RESPONSE trial17. Treatment 
discontinuation occurred more frequently for patients treated with ruxolitinib, with 35 patients 
discontinuing treatment compared to 9 discontinuations in the BAT arm. However, 30 BAT patients 
switched their initially assigned BAT treatment for various reasons, which indicates a similar rate of 
treatment ineffectiveness or intolerance. For the first time, we show baseline anemia predicted for 
treatment emergent anemia and thrombocytopenia. 
Patients with ET have a high burden of symptoms, which have been consistently reported to affect 
their quality of life37. The symptom response rate, defined as a 50% reduction in TSS, during the first 
12 months did not significantly differ between the two arms. However, maximum percentage TSS 
reduction during the first 12 months of treatment was significantly greater for ruxolitinib compared 
to BAT and was more rapid in the ruxolitinib arm. Longitudinally, mean TSS and individual symptom 
of pruritus were significantly lower for ruxolitinib, with trends observed for improved concentration, 
lower anxiety/depression and higher ability to perform usual activities for ruxolitinib arm compared 
to BAT indicating a novel and important benefit to ET patients of ruxolitinib therapy. 
Limitations of our trial include that the trial reflected “real life practice” in use of diagnostic criteria 
and selection of BAT therapies. The majority of our centers used either BCSH (n=18) or WHO (n=10) 
or both (n=3) diagnostic criteria thus perhaps illustrating non-standardized diagnostic processes, 
however this is a second line study and BCSH/WHO criteria both perform equally well29 in addition 
transformation was excluded at study entry. Guidelines recommend anagrelide or IFN as second line 
therapy for ET, many BAT patients had already been treated with these drugs (25 received 
interferon, 7 anagrelide and 7 both agents) before study entry, and overall 79% received them 
before or during the study. The use of HC as a BAT and frequent switching of BAT therapies in 30 BAT 
patients also reflect real-life constraints and limited treatment options for ET patients with 
resistance/intolerance to HC and highlight the need for newer therapies in this field. 
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In conclusion, the MAJIC-ET trial suggests that ruxolitinib does not have improved treatment efficacy 
compared to BAT for most clinically relevant events. Symptom responses were superior with 
ruxolitinib therapy but there was no difference in this study for control of blood counts or other 
relevant endpoints such as transformation, thrombosis or hemorrhage.  
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Figure 1. Dose of Ruxolitinib received throughout study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18                                                  BLOOD/2017/785790    v 2.0 Resubmission MAJIC ET_Main 
Manuscript 
 
Figure 2. Trial consort diagram at 2 year follow up 
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Figure 3. Changes in ET Related Symptom Burden during year 1 of the MAJIC-ET trial 
Figure 3A. 
 
Figure 3B.  
 
Figure 3C. 
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Figure Legends 
Figure 1 
Figure illustrating doses of ruxolitinib throughout the MAJIC-ET trial 
 
Figure 2 
Trial consort diagram at 2 year follow up 
 
Figure 3 
Changes in ET Related Symptom Burden during year 1 of the MAJIC-ET trial 
Figure 3A shows a waterfall plot of maximum percentage change in the MPN SAF TSS score, dotted 
line indicates 50% reduction in TSS 
Figure 3B shows mean MPN-SAF TSS throughout the first year of the trial there was a consistent 
trend for reduction for ruxolitinib 
Figure 3C shows the mean MPN-SAF score for itching during the first 12 months of the MAJIC-ET trial 
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Tables   
Table 1. Baseline characteristics by treatment  
 Best Available Therapy (52) Ruxolitinib (58) Overall  (110) 
Age 
Mean (sd) [Range] 65.6 (13.5) [37.2, 85.4] 62.9 (12.3)  [34.5, 90.5] 64.2 (12.9)[34.5, 90.5] 
Gender, n (%) 
Female 30 (57.7) 36 (62.1) 66 (60.0) 
Male 22 (42.3) 22 (37.9) 44 (40.0) 
Mutation status, n (%) 
JAK2V617F Positive 26 (50.0) 28 (48.3) 54 (49.1) 
CALR mutation positive 14 (26.9) 20 (34.5) 34 (30.9) 
MPL mutation positive 3 (5.8) 3 (5.2) 6  (5.5) 
Triple negative 7 (13.5) 6(10.3) 13(11.8) 
Not run 2 (3.8) 1 (1.7) 3 (2.7) 
HC Resistant or Intolerant*,  n (%) 
Resistant 25 (48.1) 28 (48.3) 53 (48.2) 
Intolerant 27 (51.9) 30 (51.7) 57 (51.8) 
Time from diagnosis to randomization, years** 
Mean (sd) [Range] 6.9 (5.8) [.4, 23.6] 10.4 (6.7) [.7, 31.2] 8.8 (6.5)[.4, 31.2] 
Hemoglobin, g/L** 
Mean (sd)  [Range] 126 (17) [90.0, 160.0] 119 (17) [87.0, 152.0] 122 (17) [87.0, 160.0] 
Platelet count x 10 
9 
/ L 
Mean (sd) [Range] 573.0 (227.1) [166.0, 1406.0] 545.4 (215.3) [89.0, 1139.0] 558.4 (220.4) [89.0, 1406.0] 
WBC count x 10 
9 
/ L 
Mean (sd) [Range] 6.8 ( 2.7) [2.8, 15.2] 7.5 ( 4.8) [1.7, 29.8] 7.2 ( 3.9) [1.7, 29.8] 
Hematocrit 
Mean (sd) [Range] 0.4 ( 0.1) [0.3, 0.5] 0.4 ( 0.1) [0.3, 0.5] 0.4 ( 0.1) [0.3, 0.5] 
Spleen size 
Enlarged 9 14 23 
Normal 38 37 75 
Splenectomy 2 3 5 
Missing 3 4 7 
Number of Previous Therapies, n (%) 
1 15(28.8) 14 (24.1) 28 (26.4) 
2 20 (38.5) 24 (41.4) 44 (40.0) 
3 8 (15.4) 12 (20.7) 20 (18.2) 
4 5 (9.6) 5 (8.6) 10 (9.1) 
5 2 (3.8) 2 (3.4) 4 (3.6) 
6 2 (3.8) 0 (.0) 2 (1.8) 
9 0 (.0) 1 (1.7) 1 (.9) 
Total number of previous therapies by treatment, number (%) ¥ 
Hydroxycarbamide 59 (52.2) 70 (58.8) 129 (55.6) 
Anagrelide 29 (25.7) 31 (26.1) 60 (25.9) 
Interferon 7 ( 6.2) 11 (9.2) 18 (7.8) 
Pegylated  Interferon 2 (1.8) 2 (1.7) 4 (1.7) 
Busulfan 8 (7.1) 1 (.8) 9 (3.9) 
32P 3 (2.7) 1 (.8) 4 (1.7) 
Pipobroman 1 (.9) 1 (.8) 2 (.9) 
Fedratinib 1 (.9) 1 (.8) 2 (.9) 
Vorinostat 2 (1.8) 0 (.0) 2 (.9) 
Thalidomide 0 (.0) 1 (.8) 1 (.4) 
Missing 1 (.9) 0 (.0) 1 (.4) 
HC Hydroxycarbamide; WBC white blood cell; *25 patients were both resistant and intolerant. These patients have been 
included as resistant; **Time from diagnosis to randomization and baseline hemoglobin were different between the two 
treatment arms; 
¥
 Patients were allowed to receive multiple therapies, therefore total number of therapies in each 
category might exceed number of patients 
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Table 2. Overview of assigned therapy switches and discontinuations per treatment arm  
 
Ruxolitinib BAT Total 
Assigned therapy switches 
Patients that switched BAT therapy at least once N/A 30 30 
Total number of times BAT therapy was switched N/A 86 86 
Discontinuations 
Transformation 9 3 12 
Loss of response 11 0 11 
Lack of efficacy 5 1 6 
Toxicity 
Anemia 2 0 2 
Other 3 1 4 
Other 3 3 6 
Death 1 2 3 
Withdrawal of consent 1 0 1 
Total 35 10 45 
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Table 3. Thrombotic and hemorrhagic events  
  
  
BAT Ruxolitinib 
Total Grade 
1&2 
Grade 
3&4 
Grade 
5 
Grade 
1&2 
Grade  
3&4 
Grade 5 
Hemorrhagic events 
Hematuria 1 0 0 0 0 0 1 
Intracranial hemorrhage 0 0 1 0 0 0 1 
Oral hemorrhage 1 0 0 1 0 0 2 
Rectal hemorrhage 1 1 0 0 0 0 2 
Total 3 1 1 1 0 0 6 
Thrombotic events ᶧ 
Chest pain - cardiac 0 1 0 0 0 0 1 
Myocardial infarction 0 0 0 0 2 0 2 
Cerebrovascular ischemia 1 0 0 0 0 0 1 
Retinal vascular disorder 1 0 0 1 0 0 2 
Thromboembolic 
events 
PE 0 0 0 0 3* 0 3 
DVT 0 0 0 1 1 0 2 
Calf vein DVT 0 0 0 0 1 0 1 
Transient ischemic attacks 2 0 0 2 0 0 4 
Total 4 1 0 4 7 0 16 
PE Pulmonary Embolism; DVT Deep Vein Thrombosis 
ᶧ The death of a ruxolitinib treated patient due to ischemic cardiomyopathy occurred more than 30 
days past treatment and is therefore not recorded as an event 
* 1 patient experienced PE and DVT at the same time, but was counted in the PE category 
 
 
